Healthcare / Medical Instruments & SuppliesShanghai
$12.09
-0.50 (-3.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-9.5M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
44.8x
↑EV/EBITDA
16.3x
↑ROE
4.3%
↑Gross Margin
44.7%
↓Debt/Equity
0.34
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.2%
FCF CAGR
-16.0%
FCF margin
7.6%
FCF / Net income
1.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.63B · net income $76.3M · FCF $124.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.63B | $1.63B | $1.51B | $1.39B | $1.36B |
| Net Income | $76.3M | $76.3M | $219.4M | $192.5M | $166.6M |
| EBITDA | $239.2M | $239.2M | $349.5M | $319.0M | $279.0M |
| EPS | 0.26 | 0.26 | 0.75 | 0.66 | 0.57 |
| Gross Margin | 44.7% | 44.7% | 44.5% | 45.9% | 43.2% |
| Operating Margin | 18.7% | 18.7% | 17.8% | 17.8% | 15.8% |
| Net Margin | 4.7% | 4.7% | 14.5% | 13.9% | 12.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.34 | 0.34 | 0.26 | 0.21 | 0.15 |
| Current Ratio | 1.83 | 1.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $124.1M | $124.1M | $-9.5M | $-135.4M | $209.7M |
| Returns | |||||
| ROE | 4.3% | 4.3% | 11.6% | 10.6% | 9.7% |
| Valuation | |||||
| P/E | 44.78 | 44.78 | 15.39 | 20.65 | 36.84 |
| EV/EBITDA | 16.28 | 16.28 | 10.23 | 12.72 | 21.52 |
| P/B | 2.01 | 2.01 | 1.79 | 2.19 | 3.56 |
| Growth & Yield | |||||
| Revenue Growth | 8.1% | 8.1% | 8.8% | 1.8% | — |
| EPS Growth | -65.3% | -65.3% | 13.6% | 15.8% | — |
| Dividend Yield | 7.9% | 7.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
60.4%
EPS terminal req.
$1.07
Spread vs growth
-125.7%
5Y implied EPS CAGR
37.9%
EPS terminal req.
$1.30
Spread vs growth
-103.3%
10Y implied EPS CAGR
23.2%
EPS terminal req.
$2.09
Spread vs growth
-88.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.5%
Start / end P/E
16.5x → 46.5x
EPS bridge
0.75 → 0.26
Residual
-118.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.